There are currently 633 clinical trials in Charleston, South Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical University of South Carolina, GSK Investigational Site, Hollings Cancer Center at Medical University of South Carolina and Medical University of South Carolina (MUSC). Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441
Recruiting
The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: MUSC Hollings Cancer Center, Charleston, South Carolina
Conditions: Endometrial Cancer
Register for Updates
A Pilot Study of a Remote ADHD Monitoring Program
NCT06743425
Recruiting
RAMP is a pilot study examining the use of an Attention-Deficit/Hyperactivity Disorder (ADHD) Monitoring Program during the early stages of treating ADHD in children living in rural settings. This trial will enroll 36 caregiver/infant dyads across 2 sites and will evaluate feasibility endpoints rather than clinical outcomes. Enrolled participants will be randomized 1:1 to the intervention group (RAMP reports) or control group (digital education handouts). The study duration is 10 months, includi... Read More
Gender:
ALL
Ages:
Between 5 years and 11 years
Trial Updated:
06/23/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Attention-deficit/Hyperactivity Disorder, ADHD
Register for Updates
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865
Recruiting
The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is. Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse e... Read More
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
06/21/2025
Locations: Clinical Trials of South Carolina - Charleston, Charleston, South Carolina
Conditions: Osteoarthritis (OA) of the Knee
Register for Updates
RESPONDER-HF Trial
NCT05425459
Recruiting
Multicenter, Prospective, Randomized, Sham Controlled, Double Blinded Clinical Trial, with; 1:1 randomization
Gender:
ALL
Ages:
40 years and above
Trial Updated:
06/19/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Heart Failure, Heart Failure, Diastolic
Register for Updates
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
NCT06225596
Recruiting
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/19/2025
Locations: Medical University of South Carolina (MUSC) - Hollings Cancer Center, Charleston, South Carolina
Conditions: Metastatic Urothelial Cancer
Register for Updates
Pulmonary Embolism - Thrombus Removal With Catheter-Directed Therapy
NCT05591118
Recruiting
PE-TRACT is an open-label, assessor-blinded, randomized trial, aiming to compare catheter-directed therapy (CDT) and anticoagulation (CDT group) with anticoagulation alone (No-CDT) in 500 patients with submassive PE, proximal pulmonary artery thrombus and right ventricular dilation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Pulmonary Embolism
Register for Updates
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy). The planned duration of treatment in either arm within the study will be 7 years.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/18/2025
Locations: Research Site, Charleston, South Carolina
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array
NCT06598059
Recruiting
This clinical study will test a new type of cochlear implant known as CI632D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation and reduce tissue injury, which is common after any type of surgery. The goal is to learn if the dexamethasone in the CI632D implant lessens these reactions inside the ear following surgery and if this makes the implant work as well, or even better, in improving hearing than what... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/18/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Hearing Loss
Register for Updates
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
NCT05064553
Recruiting
The primary objective is to assess overall sensitivity and specificity of Oncoguard™ Liver for hepatocellular cancer (HCC) detection in a surveillance population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Ralph H Johnson VAMC, Charleston, South Carolina
Conditions: Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatitis B, Cirrhosis, Liver Cancer
Register for Updates
Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy
NCT06138873
Recruiting
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise esti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Ventricular Tachycardia, Ischemic Cardiomyopathy
Register for Updates
Cold Atmospheric Plasma Device Extension Study
NCT05937672
Recruiting
Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearan... Read More
Gender:
ALL
Ages:
Between 4 years and 21 years
Trial Updated:
06/16/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Verruca Vulgaris, Molluscum Contagiosum
Register for Updates
StrokeNet Thrombectomy Endovascular Platform
NCT06289985
Recruiting
STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/16/2025
Locations: Medical University of South Carolina University Hospital, Charleston, South Carolina
Conditions: Ischemic Stroke
Register for Updates